Stock listing
NASDAQ:ARWR Arrowhead Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Arrowhead Pharmaceuticals, Inc.
Follow Arrowhead Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ARWR
$41.37 USD -1.74 (-4.0%)
Close on Nov 20, 2026
- Day range
- $41.17 – $44.80 USDNov 20, 2026
- Volume
- 3.91M sharesNov 20, 2026
- Market cap
- $5.85B USDAt the close on Nov 20, 2026 · price × 141.4M shares outstanding
- 52-week range
- $37.43 – $95.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $128.4M USDMedian day 1.63M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ARWR · Home | $41.37 USD | -1.74 (-4.0%) | 3,906,214 | $43.42 | $44.80 | $41.17 | $43.11 | Close on Nov 20, 2026 |
| B3:A2RR34 | 30.84 BRL | -0.78 (-2.5%) | — | 30.84 | 30.84 | 30.84 | 31.62 | Close on Nov 19, 2026 |
| LSE:0HI3 | $42.35 USD | -0.92 (-2.1%) | 1,376 | $43.50 | $44.58 | $42.35 | $43.27 | Close on Nov 20, 2026 |
| Frankfurt:HDP1 | €37.74 EUR | -1.94 (-4.9%) | — | €39.51 | €39.51 | €37.74 | €39.68 | Close on Nov 20, 2026 |
| Munich:HDP1 | €39.47 EUR | -0.29 (-0.7%) | — | €39.47 | €39.47 | €39.47 | €39.76 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARWR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $41.37 | -1.74 | -4.0% | $43.42 | $44.80 | $41.17 | 3,906,214 | |
| $43.11 | +0.12 | +0.3% | $42.54 | $43.99 | $42.46 | 2,421,436 | |
| $42.99 | -1.22 | -2.8% | $44.15 | $44.55 | $42.07 | 3,703,441 | |
| $44.21 | -3.57 | -7.5% | $47.12 | $47.41 | $44.07 | 1,861,868 | |
| $47.78 | +0.63 | +1.3% | $47.68 | $48.29 | $44.52 | 3,113,473 | |
| $47.15 | -2.21 | -4.5% | $48.99 | $48.99 | $46.98 | 2,154,291 | |
| $49.36 | +0.36 | +0.7% | $49.65 | $49.74 | $47.66 | 2,529,166 | |
| $49.00 | -0.24 | -0.5% | $48.61 | $50.56 | $47.90 | 2,637,081 | |
| $49.24 | -8.92 | -15.3% | $52.49 | $53.63 | $46.45 | 8,053,436 | |
| $58.16 | +0.70 | +1.2% | $58.21 | $58.71 | $57.00 | 1,363,194 | |
| $57.46 | -4.19 | -6.8% | $61.65 | $61.73 | $57.24 | 1,804,873 | |
| $61.65 | +2.12 | +3.6% | $61.75 | $61.99 | $59.06 | 1,487,357 | |
| $59.53 | -0.04 | -0.1% | $59.39 | $60.89 | $59.25 | 1,327,132 | |
| $59.57 | -0.33 | -0.6% | $60.55 | $61.17 | $59.41 | 1,306,405 | |
| $59.90 | -0.59 | -1.0% | $59.75 | $61.50 | $58.74 | 1,124,504 | |
| $60.49 | +0.28 | +0.5% | $60.74 | $61.88 | $59.75 | 1,274,373 | |
| $60.21 | +1.18 | +2.0% | $58.64 | $60.24 | $58.20 | 1,247,893 | |
| $59.03 | +0.05 | +0.1% | $59.02 | $60.47 | $58.01 | 2,118,834 | |
| $58.98 | +0.96 | +1.7% | $58.43 | $59.63 | $58.17 | 979,780 | |
| $58.02 | -0.34 | -0.6% | $57.94 | $58.38 | $56.56 | 871,717 | |
| $58.36 | -0.48 | -0.8% | $58.06 | $59.90 | $56.97 | 1,036,454 | |
| $58.84 | -0.08 | -0.1% | $59.42 | $60.46 | $58.82 | 1,371,453 | |
| $58.92 | +1.69 | +3.0% | $56.93 | $59.57 | $56.92 | 1,742,297 | |
| $57.23 | +1.33 | +2.4% | $56.96 | $57.30 | $56.05 | 1,646,984 | |
| $55.90 | -2.60 | -4.4% | $58.45 | $58.45 | $55.83 | 1,772,800 | |
| $58.50 | +0.13 | +0.2% | $58.50 | $59.40 | $57.40 | 2,009,600 | |
| $58.37 | +0.24 | +0.4% | $58.48 | $60.53 | $57.15 | 4,160,100 | |
| $58.13 | -2.60 | -4.3% | $60.04 | $60.73 | $58.08 | 2,260,400 | |
| $60.73 | -2.02 | -3.2% | $62.49 | $62.50 | $60.48 | 1,194,400 | |
| $62.75 | +2.01 | +3.3% | $60.72 | $62.99 | $60.44 | 2,765,700 | |
| $60.74 | -0.74 | -1.2% | $60.54 | $61.13 | $59.21 | 1,784,700 | |
| $61.48 | -0.06 | -0.1% | $61.63 | $62.75 | $60.78 | 1,819,200 | |
| $61.54 | -0.81 | -1.3% | $62.86 | $63.19 | $60.56 | 1,675,500 | |
| $62.35 | -1.84 | -2.9% | $64.76 | $64.76 | $62.22 | 2,249,400 | |
| $64.19 | -0.60 | -0.9% | $65.57 | $66.16 | $63.99 | 1,487,600 | |
| $64.79 | -0.66 | -1.0% | $65.00 | $65.76 | $64.50 | 1,521,700 | |
| $65.45 | -0.80 | -1.2% | $66.80 | $66.80 | $65.09 | 1,742,700 | |
| $66.25 | +0.79 | +1.2% | $65.46 | $66.83 | $64.57 | 2,869,600 | |
| $65.46 | -0.46 | -0.7% | $65.00 | $66.11 | $63.99 | 1,589,700 | |
| $65.92 | -0.15 | -0.2% | $66.50 | $67.44 | $65.40 | 1,616,200 | |
| $66.07 | -0.89 | -1.3% | $67.00 | $67.45 | $65.46 | 1,626,300 | |
| $66.96 | -4.90 | -6.8% | $72.16 | $72.49 | $66.27 | 2,554,500 | |
| $71.86 | +3.07 | +4.5% | $68.85 | $72.37 | $68.08 | 3,115,700 | |
| $68.79 | +2.31 | +3.5% | $67.46 | $69.26 | $66.06 | 2,347,400 | |
| $66.48 | -1.26 | -1.9% | $67.83 | $68.05 | $66.36 | 4,016,000 | |
| $67.74 | +1.95 | +3.0% | $68.91 | $68.91 | $67.00 | 3,210,100 | |
| $65.79 | -4.88 | -6.9% | $70.41 | $71.93 | $64.50 | 5,111,900 | |
| $70.67 | -10.00 | -12.4% | $82.89 | $83.55 | $70.61 | 4,369,900 | |
| $80.67 | -2.18 | -2.6% | $82.98 | $83.27 | $79.93 | 1,329,200 | |
| $82.85 | +0.09 | +0.1% | $83.75 | $85.98 | $82.36 | 1,335,800 | |
| $82.76 | +0.13 | +0.2% | $81.58 | $83.38 | $80.33 | 1,020,300 | |
| $82.63 | -2.48 | -2.9% | $84.65 | $87.20 | $82.16 | 3,668,200 | |
| $85.11 | -1.23 | -1.4% | $84.22 | $86.96 | $83.54 | 1,567,700 | |
| $86.34 | -0.15 | -0.2% | $85.87 | $86.96 | $84.20 | 757,600 | |
| $86.49 | +1.12 | +1.3% | $85.18 | $86.79 | $83.46 | 1,370,500 | |
| $85.37 | +2.63 | +3.2% | $82.87 | $85.47 | $82.09 | 1,525,400 | |
| $82.74 | +0.35 | +0.4% | $81.14 | $83.27 | $80.76 | 1,330,600 | |
| $82.39 | -2.52 | -3.0% | $83.13 | $83.76 | $80.75 | 1,595,500 | |
| $84.91 | -3.68 | -4.2% | $87.99 | $88.25 | $84.20 | 1,282,200 | |
| $88.59 | -0.53 | -0.6% | $89.59 | $89.59 | $88.06 | 857,500 | |
| $89.12 | +0.24 | +0.3% | $88.45 | $89.83 | $86.80 | 859,500 | |
| $88.88 | +2.15 | +2.5% | $88.00 | $90.21 | $87.00 | 983,000 | |
| $86.73 | -0.38 | -0.4% | $86.77 | $87.01 | $85.50 | 1,104,400 | |
| $87.11 | -0.36 | -0.4% | $87.90 | $88.46 | $85.94 | 1,089,800 | |
| $87.47 | -1.94 | -2.2% | $88.23 | $88.45 | $85.90 | 896,800 |
Splits
2 splits since 2004 · NASDAQ:ARWR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-65 | Consolidation |
- Ticker
- NASDAQ:ARWR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Latest earnings call · Nov 12, 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2026 Earnings Call
Replay and transcript
Latest deck · Oct 14, 2026
Technical Presentation (October 2026)
Technical · 47 slides
Latest news
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 17, 2026
Closed $43.11 (+0.3%) on Nov 18, 2026
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
Nov 12, 2026
Closed $47.78 (+1.3%) on Nov 13, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 9, 2026
Closed $49.00 (-0.5%) on Nov 10, 2026
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
Nov 7, 2026
Closed $49.24 (-15.3%) on Nov 9, 2026
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
Nov 4, 2026
Closed $61.65 (+3.6%) on Nov 4, 2026
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
Nov 3, 2026
Closed $61.65 (+3.6%) on Nov 4, 2026
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Nov 2, 2026
Closed $59.57 (-0.6%) on Nov 2, 2026
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Oct 27, 2026
Closed $59.03 (+0.1%) on Oct 27, 2026
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Oct 14, 2026
Closed $58.37 (+0.4%) on Oct 14, 2026
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Oct 7, 2026
Closed $61.48 (-0.1%) on Oct 7, 2026
Arrowhead Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 55 in the last 12 months · 292 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 12, 2026
- Decks
- 16 decks · latest Oct 14, 2026
Where Arrowhead Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ARWR · Home listing · This page | NASDAQ | United States | USD |
| gettex:HDP1 | gettex | Germany | EUR |
| B3:A2RR34 | B3 | Brazil | BRL |
| LS Exchange:A2AGYB | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AGYB | Lang & Schwarz | Germany | EUR |
| BMV:ARWR | BMV | Mexico | MXN |
| LSE:0HI3 | LSE | United Kingdom | USD |
| BOATS:ARWR | BOATS | United States | USD |
| Tradegate:HDP1 | Tradegate | Germany | EUR |
| Frankfurt:HDP1 | Frankfurt | Germany | EUR |
| Stuttgart:HDP1 | Stuttgart | Germany | EUR |
| BIVA:ARWR | BIVA | Mexico | MXN |
| BX Swiss:HDP1 | BX Swiss | Switzerland | CHF |
| Dusseldorf:HDP1 | Dusseldorf | Germany | EUR |
| Hamburg:HDP1 | Hamburg | Germany | EUR |
| Munich:HDP1 | Munich | Germany | EUR |
| Hanover:HDP1 | Hanover | Germany | EUR |
| Xetra:HDP1 | Xetra | Germany | EUR |
Valuation
EV/sales 10.3× against a median of 33.4×: 2nd lowest of 6 Biotechnology companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.66B USD
- P/E
- Loss
- EV/sales
- 10.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 116×
- Gross margin
- Not reported
- Operating margin
- −156.9%
- Net margin
- −160.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.05B | US$4.77B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Median of the others | US$6.20B | US$5.63B | 16.9× | 33.4× | 20.1× | 6.7× | −36.4% | 0.0× | 1.34 |
Forecasts
10 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 105.86 USD · Analysts' mean
- EPS, year to Sep 2027
- -5.56 · 10 analysts
- Revenue, year to Sep 2027
- 310.5M · 15 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Christopher Anzalone | President, CEO and Chairman of the Board |
| Daniel Apel | Chief Financial Officer |
| Patrick O’Brien | Chief Operating Officer |
| James Hamilton | Chief Medical Officer, Head of R&D |
| Tao Pei | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Christopher Anzalone | President, CEO and Chairman of the Board |
| Hongbo Lu | |
| Matt Cohen | Board Member |
| Mauro Ferrari | |
| Michael Perry | |
| Oye Olukotun | |
| Victoria Vakiener | |
| William Waddill |
Events
Calls
| Call | When | Status |
|---|---|---|
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2026 Earnings Call | Thu, Nov 12, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2026 Earnings Call | Thu, Feb 05, 2026 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2025 Earnings Call | Tue, Nov 25, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2025 Earnings Call | Mon, May 12, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2025 Earnings Call | Mon, Feb 10, 2025 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2024 Earnings Call | Tue, Nov 26, 2024 · 4:30 PM ET | Replay |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2026 | Nov 12, 2026 · After close | +1.3% |
| Q3 2026 | Aug 4, 2026 · After close | −3.0% |
| Q2 2026 | May 7, 2026 · After close | −6.8% |
| Q1 2026 | Feb 5, 2026 · After close | −0.2% |
| Q4 2025 | Nov 25, 2025 | +30.4% |
| Q3 2025 | Aug 7, 2025 · After close | +2.2% |
| Q2 2025 | May 12, 2025 · After close | +9.4% |
| Q1 2025 | Feb 10, 2025 · After close | −5.2% |
| Q4 2024 | Nov 27, 2024 · Before open | +24.2% |
| Q3 2024 | Aug 8, 2024 · After close | −9.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | May 9, 2024 · After close | −10.7% |
| Q1 2024 | Feb 6, 2024 · After close | −4.7% |
| Q4 2023 | Nov 29, 2023 · After close | −26.9% |
| Q3 2023 | Aug 7, 2023 · After close | −10.8% |
| Q2 2023 | May 2, 2023 · After close | +13.6% |
| Q1 2023 | Feb 6, 2023 · After close | +0.3% |
| Q4 2022 | Nov 28, 2022 · After close | +7.1% |
| Q3 2022 | Aug 4, 2022 · After close | −0.4% |
| Q2 2022 | May 10, 2022 · After close | −15.6% |
| Q1 2022 | Feb 2, 2022 · After close | −6.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 47 slides | Oct 14, 2026 |
| Technical Presentation (June 2026) | Technical | 57 slides | Jun 29, 2026 |
| Technical Presentation (January 2026) | Technical | 65 slides | Jan 6, 2026 |
| TIDES USA 2026 | Conference | 26 slides | 2026 |
| Investor Presentation (December 2025) | Investor deck | 38 slides | December 2025 |
| Corporate Update (November 2025) | Corporate update | 43 slides | Nov 18, 2025 |
| RNA Leaders USA Congress 2025 | Conference | 25 slides | Sep 10, 2025 |
| Complement Based Drug Development Summit 2024 | Conference | 20 slides | Dec 11, 2024 |
| Technical Presentation (October 2024) | Technical | 68 slides | Oct 7, 2024 |
| American Heart Association Scientific Sessions 2023 | Conference | 14 slides | 2023 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2022) | Technical | 11 slides | 2022 |
| Arrowhead Research — Investor Presentation (April 2009) | Investor deck | 14 slides | Apr 3, 2009 |
| Arrowhead Research — Investor Presentation (March 2008) | Investor deck | 24 slides | Mar 13, 2008 |
| Arrowhead Research — Investor Presentation (March 2008) | Investor deck | 21 slides | Mar 13, 2008 |
| Technical Presentation | Technical | 14 slides | |
| Technical Presentation | Technical | 26 slides |
Financings
| Raise | Date |
|---|---|
| 0.00% convertible senior notes due 2032 Closed: US$625M raised · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets Use of proceeds: About $42.8 million for capped call transactions; remainder for general corporate purposes incl. R&D, clinical trials and commercial launch preparation | Feb 5, 2026 |
| Public offering of common stock and pre-funded warrants Closed: US$200M raised · US$64.5 a share · Jefferies +4 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets Use of proceeds: General corporate purposes incl. working capital, R&D, clinical trials and commercial launch preparation; may prepay Sixth Street loans | Feb 5, 2026 |
| Strategic investment of common stock Closed: US$325M raised · US$27.25 a share Buyers: Sarepta ($325 million of Arrowhead common stock at $27.25 per share) | Oct 21, 2025 |
| Strategic investment of common stock Closed: US$325M raised · US$27.25 a share Buyers: Sarepta Therapeutics ($325 million equity investment priced at $27.2507); Sarepta ($325 million of Arrowhead common stock at $27.25 per share) | Feb 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 450.8M | 829.4M | 3.55M | 240.7M | 243.2M | 138.3M | 88.0M | 168.8M | 16.1M | 31.4M |
| Cost of revenue | 23.9M | 18.6M | 12.5M | 10.4M | 67.4M | 63.7M | ||||
| Gross profit | 829.4M | -15.0M | 228.2M | 243.2M | 138.3M | 88.0M | 168.8M | 16.1M | 31.4M | |
| Research and development | 739.1M | 607.2M | 505.9M | 353.2M | 297.3M | 206.3M | 128.9M | 81.0M | 53.0M | 50.9M |
| Selling, general and administrative | 202.0M | 123.9M | 98.8M | 90.9M | 124.4M | 81.0M | 52.3M | 26.6M | 19.1M | 17.5M |
| Operating income | -707.2M | 98.3M | -601.1M | -205.0M | -178.5M | -149.0M | -93.2M | 61.2M | -55.9M | -37.0M |
| Depreciation and amortization | 24.7M | 22.2M | 16.9M | 10.7M | 8.70M | 6.60M | 4.20M | 2.70M | 3.00M | 2.99M |
| EBITDA | -682.5M | 120.5M | -584.2M | -194.3M | -169.8M | -142.4M | -89.0M | 63.9M | -52.9M | -34.0M |
| Interest expense | 93.7M | 89.4M | 32.4M | 18.3M | 0 | 0 | 9.19B | 6.96B | 1.05B | 415.1M |
| Income before tax | -723.9M | 51.5M | -612.5M | -206.5M | -172.7M | -140.8M | -84.6M | 68.1M | -54.4M | -34.4M |
| Income tax | -6.78M | 21.4M | -2.77M | 2.78M | 3.79M | 2.00K | 2.00K | 174.0K | 2.40K | 2.40K |
| Net income | -724.2M | -1.63M | -599.5M | -205.3M | -176.1M | -140.8M | -84.6M | 68.0M | -54.5M | -34.4M |
| Earnings per share, basic | -5.11 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 |
| Earnings per share, diluted | -5.11 | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | -0.47 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 62.7M | 226.5M | 102.7M | 110.9M | 108.0M | 184.4M | 143.6M | 221.8M | 30.1M | 24.8M |
| Short-term investments | 1.13B | 692.8M | 578.3M | 292.7M | 0 | 126.7M | 85.0M | 36.9M | 46.4M | 40.8M |
| Receivables | 9.93M | 6.82M | 0 | 0 | 1.41M | 10.3M | 846.0K | 661.4K | 327.4K | 67.8K |
| Inventory | 9.07M | 0 | -21.6M | 4.36M | 4.25M | 3.32M | 1.27M | 867.4K | ||
| Current assets | 1.29B | 950.6M | 695.5M | 416.5M | 405.3M | 384.6M | 322.4M | 265.2M | 78.8M | 67.9M |
| Property, plant and equipment | 371.3M | 382.5M | 386.0M | 290.3M | 110.3M | 48.7M | 30.9M | 23.2M | 13.9M | 15.5M |
| Goodwill | 15.4M | 17.1M | 18.8M | 20.5M | ||||||
| Total assets | 1.74B | 1.39B | 1.14B | 765.6M | 691.9M | 710.1M | 522.5M | 349.8M | 111.6M | 104.0M |
| Accounts payable | 30.1M | 17.7M | 11.4M | 35.9M | 2.87M | 9.46M | 6.83M | 7.65M | 2.81M | 4.08M |
| Current liabilities | 311.3M | 195.5M | 103.2M | 105.5M | 138.8M | 146.5M | 40.7M | 97.1M | 12.4M | 18.7M |
| Long-term debt | 214.9M | 393.2M | 2.10M | 2.33M | ||||||
| Total debt | 366.3M | 851.9M | 383.5M | 81.6M | 25.5M | 21.1M | 2.33M | 2.53M | ||
| Total liabilities | 881.9M | 948.7M | 478.4M | 273.6M | 301.3M | 60.7M | 105.8M | 16.4M | 23.2M | |
| Shareholders' equity | 50.3M | 466.1M | 185.4M | 271.3M | 398.5M | 408.8M | 461.8M | 244.6M | 95.8M | 81.4M |
| Shares outstanding | 141.3M | 135.7M | 124.4M | 107.3M | 106.0M | 104.3M | 102.4M | 95.5M | 88.5M | 74.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -271.9M | 179.6M | -462.9M | -153.9M | -136.1M | 171.3M | -95.8M | 173.0M | -47.2M | -23.9M |
| Capital spending | -12.0M | -22.7M | -141.5M | -176.7M | -52.8M | -23.6M | -12.0M | -12.0M | -1.42M | -7.92M |
| Free cash flow | -283.9M | 156.9M | -604.3M | -330.6M | -188.9M | 147.7M | -107.8M | 161.0M | -48.6M | -31.9M |
| Cash from investing | -670.5M | -129.3M | -420.1M | -96.2M | -5.42M | -141.7M | -240.8M | -47.7M | -7.43M | -48.6M |
| Cash from financing | 776.8M | 74.0M | 870.5M | 253.1M | 65.2M | 11.3M | 257.9M | 66.4M | 60.0M | 12.1M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 5.19M | 11.3M | 257.9M | 68.8M | -54.7K | -438.8K | ||||
| Change in cash | -165.6M | 124.3M | -12.4M | 3.01M | -76.4M | 40.9M | -78.2M | 191.7M | 5.29M | -60.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Nov 12, 2026 | Annual report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Management or board change | SEC |
| 144/A · Notice of proposed sale, amended | May 19, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | May 19, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | May 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 20, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Jan 26, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jan 26, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 26, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 8, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 305B2 | Jan 8, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Jan 8, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Jan 7, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 6, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 6, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Dec 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 28, 2025 | Other filings | SEC |
| 10-K · Annual report | Nov 25, 2025 | Annual report | SEC |
| 8-K · Current report | Nov 25, 2025 | Results | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Oct 10, 2025 | Annual report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 15, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 10, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2025 | Other filings | SEC |
| 424B7 · Prospectus | Mar 7, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2025 | Results | SEC |
| 10-Q · Quarterly report | Feb 10, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 7, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Feb 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jan 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jan 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 424B7 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 17, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Dec 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 26, 2024 | Results | SEC |
| 10-K · Annual report | Nov 26, 2024 | Annual report | SEC |
| 5 · Annual statement of ownership | Nov 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2024 | Other filings | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 2, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Arrowhead Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 141,368,004
- Fully diluted
- 141,564,889
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 141,368,004 | Nov 5, 2026 |
| Options and RSUs | 196,885 | Oct 22, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 141,368,004 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Douglas S Ingram Other companies: Relay Therapeutics, Inc. (Director · Since at least Jul 15, 2020); Sarepta Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Jun 26, 2017); Endo International PLC (Director · May 5, 2016 – Jun 9, 2017 · Past); Skye Bioscience, Inc. (Vice Chairman, Director · Jun 1, 2015 – Oct 20, 2015 · Past); Volcom Inc (Director · Aug 3, 2006 – Jun 23, 2011 · Past) | Director · Since at least Feb 6, 2025 |
| William Waddill Other companies: Annexon, Inc. (LEAD INDEPENDENT DIRECTOR · Since at least Aug 12, 2021); Protagonist Therapeutics, Inc. (Independent Director · Since at least Aug 10, 2016); Turnstone Biologics Corp. (Director · Apr 15, 2024 – Jun 3, 2024 · Past); Calithera Biosciences, Inc. (SR. VP & CFO · Oct 1, 2014 – Nov 29, 2016 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Financial Officer · Jul 17, 2013 – Jul 23, 2013 · Past) | Director · Since at least Dec 20, 2017 |
| Adeoye Olukotun Other companies: Tonix Pharmaceuticals Holding Corp. (Director · Since at least Sep 5, 2018); Genesis Unicorn Capital Corp (Chief Executive Officer · Feb 14, 2022 – Feb 14, 2022 · Past); Via Pharmaceuticals Inc (Chief Medical Officer · Aug 2, 2007 – Dec 17, 2007 · Past); Icagen Inc (Director · Aug 3, 2006 – Oct 27, 2011 · Past) | Director · Since at least Sep 1, 2020 |
| Douglas B Given Other companies: Via Pharmaceuticals Inc (Director · Mar 12, 2009 – Nov 15, 2010 · Past); Aksys Ltd (Director · Jun 23, 2006 – Oct 6, 2006 · Past) | Director · Feb 16, 2012 – Dec 16, 2024 · Past |
| Hongbo Lu Other companies: Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Terns Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2024) | Director · Since at least Mar 15, 2024 |
| Marianne De Backer Other companies: Vir Biotechnology, Inc. (PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR · Since at least Apr 3, 2023); Kronos Bio Inc (Director · Jan 25, 2021 – Jun 22, 2023 · Past) | Director · Dec 12, 2019 – Jan 10, 2023 · Past |
| Michael Perry Other companies: Avita Medical, Inc. (Director · Sep 14, 2019 – Nov 21, 2022 · Past); Armata Pharmaceuticals, Inc. (Director · May 8, 2006 – Dec 31, 2019 · Past) | Director · Since at least Dec 22, 2011 |
| Victoria Vakiener Other companies: Chimerix Inc (Director · Apr 22, 2021 – Apr 21, 2025 · Past); Epizyme Inc (Chief Commercial Officer · Sep 18, 2020 – Feb 4, 2021 · Past) | Director · Since at least May 2, 2022 |
| Bruce D Given Other companies: Encysive Pharmaceuticals Inc (President & CEO, Director · Mar 2, 2006 – Mar 14, 2007 · Past) | Chief Operating Officer · Oct 26, 2011 – Apr 27, 2020 · Past |
| Curt Bradshaw Other companies: NeuBase Therapeutics Inc (Chief Scientific Officer · Dec 1, 2020 – Dec 1, 2020 · Past) | Chief Scientific Officer · Nov 18, 2019 – Nov 19, 2020 · Past |
All 29 people
| Person | Seat |
|---|---|
| Edward W Frykman Other companies: Acacia Research Corporation (Director · Jan 3, 2006 – Mar 15, 2017 · Past) | Director · Feb 23, 2006 – Jan 1, 2018 · Past |
| James Hassard Other companies: Crinetics Pharmaceuticals, Inc. (Chief Commercial Officer · Feb 28, 2022 – Jul 5, 2024 · Past) | Chief Commercial Officer · Jan 7, 2021 – Jun 22, 2021 · Past |
| Martin Javier San Other companies: LeonaBio, Inc. (CHIEF MEDICAL OFFICER · Since at least Apr 15, 2024) | Chief Medical Officer · Nov 21, 2022 – Jan 4, 2024 · Past |
| Peter Brian Leone Other companies: Bicycle Therapeutics PLC (Chief Business Officer · May 22, 2019 – May 28, 2019 · Past) | VP, Strategic Bus. Initiatives · Mar 6, 2015 – Oct 19, 2018 · Past |
| Zhen Li Other companies: ADARx Pharmaceuticals, Inc. (President & CEO · Since at least Sep 24, 2026) | Snr. VP, Chem and Non-Clin Dev · Jan 25, 2018 – Jan 14, 2019 · Past |
| Christopher Anzalone | President, CEO and Chairman of the Board · Since at least Dec 1, 2007 |
| Daniel Apel | Chief Financial Officer · Since at least Apr 15, 2025 |
| David L Lewis | Chief Scientific Officer · Jan 2, 2014 – Jan 1, 2016 · Past |
| Edward Lee Jacobs | Subsidiary CEO · Jan 1, 2007 – Jan 1, 2007 · Past |
| James Hamilton | Chief Medical Officer, Head of R&D · Since at least Jan 12, 2024 |
| Joseph Theodore Kingsley III | Chief Financial Officer · May 26, 2006 – Mar 29, 2007 · Past |
| Kenneth Allen Myszkowski | Chief Financial Officer · Oct 20, 2020 – Jan 4, 2025 · Past |
| Matt Cohen | Board Member · Since at least Jun 17, 2026 |
| Matthew Gregory Cohen | Director · Since at least Jun 15, 2026 |
| Mauro Ferrari | Director · Since at least Aug 18, 2010 |
| Oye Olukotun | Director · Since at least Nov 5, 2026 |
| Patrick O’Brien | Chief Operating Officer · Since at least May 28, 2019 |
| Tao Pei | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Tracie Oliver | Chief Commercial Officer · Jun 20, 2022 – Jul 2, 2024 · Past |
Log in to ask 6ix AI your own questions about Arrowhead Pharmaceuticals, Inc.